If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
284
results.
Updated on
01/09/2026 [06:53:00]
Results 100 to 125 of 284
Absstract of: US20260248954A1
Generally, a polymer nanomaterial encapsulation system useful in the production of polymer encapsulated nanoparticles comprised of a hydrophobic nanoparticle encapsulated in the hydrophobic region of the polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanoparticle conjugates. Specifically, particular embodiments include a polymer nanoparticle structure including one or more of: a quantum dot and/or a superparamagnetic iron oxide nanoparticle and/or an upconverting nanoparticle, encapsulated in polystyrene-b-polyethylene glycol amine for the production of antibody conjugates useful in the capture of cellular targets.
Absstract of: WO2025090525A1
The disclosure provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells. The conjugates can be delivered to immune cells ex vivo or formulated in a pharmaceutical composition and can be directly administered to a subject in need of (i.e., via in vivo administration).
Absstract of: WO2025083423A1
The invention relates to a self-assembling conjugate molecule, the conjugate molecule comprising a hydrophobic polymer covalently bound to human serum albumin (HSA) only at residue Cys34; or a hydrophobic polymer covalently bound to a non-human serum albumin protein only at an equivalent residue to Cys34 of HSA; and associated compositions, uses and methods of treatment.
Absstract of: EP4796551A1
0001 The purpose of the invention described herein is to provide a compound having a novel chemical structure that is usable for lipid nanoparticles. Disclosed are a compound represented by formula (I) (in the formula, R<1> and R<2> are each independently a C10-24 chain hydrocarbon group, R<3> is a C1-22 chain hydrocarbon group) and lipid nanoparticles containing the compound.
Absstract of: EP4796213A1
0001 While conventional hydrogel manufacturing methods employing physical or chemical stimuli require sophisticated processes and can compromise the activity and structural integrity of particles-particularly when biological materials sensitive to external reactions are involved-the hydrogel and the preparation method thereof using an Aqueous Two-Phase System (ATPS) provided by the present invention enable the simultaneous formation of the hydrogel and encapsulation of desired nanoparticles within the hydrogel. The present invention successfully achieves the concentration of desired nanoparticles within a hydrogel with high yields through a simplified process. Furthermore, by facilitating concurrent concentration and hydrogel formation, the present invention relates to a hydrogel and a preparation method thereof using an ATPS that significantly reduces manufacturing time and costs.
Absstract of: EP4796109A2
The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and an albumin based upon the status of an mTOR-activating aberration.
Absstract of: WO2025085881A1
Nanoemulsions (NEs) and nanocapsules (NCs), are disclosed that include nanoparticles that can readily diffuse/distribute throughout the nervous system and that can deliver a therapeutic agent thereto. Methods of making and using the same also are disclosed, especially for treating diseases and/or disorders in which delivery of a therapeutic agent to and/or throughout the nervous system are needed.
Absstract of: WO2025083617A1
The present disclosure includes a composition including a) one or more nucleic acid constructs, wherein the one or more nucleic acid constructs encode: at least one of Replicase 68 (Rep68) and Replicase 78 (Rep78); and at least one protein of viral origin having nucleic acid replication and/or transgene amplification promotion activity, and b) nucleic acid construct comprising a coding region encoding at least one gene of interest (GOI) and at least one inverted terminal repeat (ITR) sequence on each side of the GOI, and methods of making and using the composition.
Absstract of: WO2025082973A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Absstract of: EP4796527A1
0001 The present invention relates to a cationic lipid and a method for preparing same, and more specifically to: a cationic lipid which, due to the specific structure thereof, forms (or is capable of forming) a complex with an anionic drug, and thus is useful for drug delivery; and a method for preparing same.
Absstract of: EP4796555A1
The present invention relates to a novel lipid compound for tissue-specific delivery and a lipid nanoparticle (LNP) composition comprising the same. The lipid nanoparticle comprises, as a component, a lipid compound modified such that an active substance therein is selectively delivered into cells of a specific tissue such as lymph nodes, spleen, retina, tumors, brain, liver, and the like in vivo, thereby preventing side effects and safely achieving desired therapeutic efficacy. These tissue-specific, non-viral LNP delivery systems can be effectively utilized for the prevention of infectious diseases and the treatment of rare and intractable (inherited) diseases (e.g., macular degeneration, diabetic retinopathy, inherited retinal diseases, cancer, brain diseases, liver diseases, etc.), where efficient and selective delivery to the targeted site in the body is crucial.
Absstract of: WO2025166213A1
This disclosure is directed to a method for treatment of cancer patients. The method comprises administering to the patient a pharmaceutical composition comprising nanoparticles of taxane modified with symmetrically and asymmetrically branched homopolymers. Particularly, this disclosure is directed to methods and single dose unit drug packages for treating head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), and other cancers with the pharmaceutical composition.
Absstract of: EP4310075A2
0001 What is described is a compound of formula (I) consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
Absstract of: WO2025106594A1
The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs comprising a package RNA and one or more fusion proteins wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95% or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or an elastin messenger RNA (mRNA) that also includes any isoforms. The present invention also provides a method of treatment of elastin deficient related illness in a subject using the pharmaceutical composition of the present inventin.
Absstract of: CN122629047A
本发明公开了一种抑制班达病毒复制的siRNA、RNA递送系统及其应用，涉及核酸药物与抗病毒治疗技术领域。针对SFTSV的S节段保守区域设计了siRNA，其不仅能靶向SFTSV的不同毒株的S节段，还能靶向其他的班达病毒的S节段，在细胞模型中可降低病毒RNA水平、病毒蛋白表达及病毒滴度，从而抑制班达病毒复制。此外，本发明还提供了RNA递送系统，可以实现siRNA的体内有效递送并增强抗病毒效果。因此，本发明提供的siRNA有望用于SFTSV等多种班达病毒感染的预防或治疗。
Absstract of: CN122624461A
本发明属于药物与疾病治疗技术领域，具体涉及7‑表紫杉醇在制备治疗非酒精性脂肪肝的药物中的用途。本发明通过体内、体外多模型验证，首次揭示7‑表紫杉醇（7‑epi‑paclitaxel）对非酒精性脂肪性肝病具有剂量依赖且可逆的“三阶”干预作用，并兼具“调脂‑抗炎‑抗纤维化”一体化优势，本发明的研究结果表明，7‑表紫杉醇可以用于制备治疗非酒精性脂肪肝的药物，同时保持极高安全性与依从性。
Absstract of: CN122624319A
本发明提供一种亲水型氧化铈纳米颗粒及其分散液。亲水型氧化铈纳米颗粒包括氧化铈纳米颗粒内核以及包覆于其表面的亲水高分子化合物，氧化铈纳米颗粒中铈元素以Ce3+和Ce4+两种价态共存。亲水高分子化合物包覆于氧化铈纳米颗粒表面，可提高其在水相体系中的分散性和稳定性。本发明还提供亲水型氧化铈纳米颗粒的制备方法，可在水相体系、常温常压条件下进行，工艺温和，操作简便，所得亲水型氧化铈纳米颗粒具有良好的自由基清除能力、分散稳定性和氧化应激调控活性，可在水体系中形成稳定分散液，并在细胞和动物氧化应激模型中表现出较好的抗氧化及组织保护作用。本发明还提供亲水型氧化铈纳米颗粒或其分散液在抗氧化、氧化应激调控及相关制剂中的应用。
Absstract of: CN122624620A
本发明公开一种高效穿透血脑屏障的负载多肽的黄精外泌体的制备方法，包括以下步骤：（1）从新鲜黄精中提取黄精外泌体，得到纯化后的黄精外泌体；（2）将多肽与纯化的黄精外泌体共孵育，得到所述高效穿透血脑屏障的负载多肽的黄精外泌体。本发明制备得到的黄精外泌体，囊泡结构完整，将其负载多肽，包封率高，达91.23%。本发明制备得到的负载多肽的黄精外泌体具有更强抗氧化能力，并更易穿透血脑屏障。一方面，黄精外泌体高效递送多肽，使多肽更好发挥改善学习记忆力的作用，另一方面，黄精外泌体和多肽协同作用，共同增强了改善学习记忆力的效果。本发明为功能因子递送系统在中枢神经系统疾病中的应用提供了新思路，具有广阔的应用前景。
Absstract of: CN122628163A
本发明涉及生物医药技术领域，具体公开了口服型双靶向布鲁氏菌病纳米疫苗CS‑CKS9‑MEV‑DCpep‑NPs的构建方法及其应用，该纳米疫苗包含壳聚糖纳米颗粒以及包封于其内部的双靶向肽疫苗CKS9‑MEV‑DCpep，所述双靶向肽疫苗CKS9‑MEV‑DCpep从N端到C端依次包含M细胞靶向肽CKS9、多表位疫苗MEV和DC靶向肽DCpep；本发明还提供了构建所述纳米疫苗的方法及其应用。本发明通过整合“生物信息学精准筛选、双靶向分子修饰以及优异载体递送”的系统性策略，成功构建了口服型CS‑CKS9‑MEV‑DCpep‑NPs纳米疫苗，其具有黏膜免疫和细胞免疫双重靶向功能，能有效诱导黏膜免疫、细胞免疫和体液免疫，并在急性和慢性感染模型中展现出优异的保护效力，从而为布鲁氏菌病的防控提供了新的有效方案。
Absstract of: CN122624437A
本发明涉及生物医药技术领域，公开了可吸入的适配体修饰二硫化钼纳米花复合物及其应用。包括二硫化钼纳米花核心、附着于二硫化钼纳米花表面的树枝状聚赖氨酸修饰层、负载于二硫化钼纳米花和/或树枝状聚赖氨酸修饰层上的阿霉素，以及通过静电组装方式结合于树枝状聚赖氨酸修饰层外表面的AS1411适配体。复合物可通过雾化吸入或气溶胶吸入方式递送至肺部病灶，并在肿瘤微环境中过氧化氢作用下发生响应性结构变化，生成活性氧，并促进阿霉素释放，从而实现化疗与化学动力治疗的协同抗肿瘤作用。本发明的复合物具有较好的胶体稳定性、载药能力、主动靶向能力和肺部局部递送潜力，可用于制备用于治疗肺癌的吸入制剂或局部给药制剂。
Absstract of: CN122624427A
本发明涉及生物医药、纳米药物递送及炎症性疾病治疗技术领域，具体涉一种pH响应型光热‑免疫调节纳米体系、制备方法及应用。本发明以pH响应高分子生物材料为初始载体，负载药物雷公藤红素（Cel）和光热试剂吲哚菁绿（ICG）得到pH响应纳米颗粒（PMCI）。最后将M2型巨噬细胞膜（M2）通过纳米膜共挤出技术包覆纳米颗粒制备出巨噬细胞膜包被的pH响应型仿生纳米体系（PMCI@M2）。经体内外实验表明，该pH响应型仿生纳米体系能够有效靶向炎症关节部位，响应释放的Cel既能够阻断凋亡相关颗粒样蛋白（ASC）/含半胱氨酸的天冬氨酸蛋白水解酶（Caspase‑1）信号通路抑制NLRP3炎症小体的组装和激活，减轻局部炎症；又通过调节M1/M2复极化，重塑免疫微环境，促进炎症消退和组织修复；还可以通过调节热休克蛋白90（HSP90）水平有效增强光热治疗效果，同时又具有生物安全性，pH响应释放等优点，为新型药剂研发设计提供新思路，对类风湿性关节炎的治疗具有重要意义。
Absstract of: CN122624423A
本发明提供了一种细胞内近红外光催化的纳米组装体及制备方法和应用，本发明的纳米组装体涉及到三种组分，一为具有近红外吸收的光催化剂，同时作为光热试剂，二为NO释放基元，三为两亲性嵌段共聚物聚乙二醇嵌段聚己内酯。通过快速纳米沉淀法，两亲性嵌段共聚物在水溶液中自组装负载光催化剂以及NO释放基元，得到纳米组装体，该纳米组装体中的光催化剂分子在光照条件下既可以作为光氧化还原催化剂激活NO供体分子释放NO，同时可以消耗细胞内NADH，还能够产生热量，可以有效杀灭三阴性乳腺癌肿瘤细胞，并在小鼠皮下肿瘤模型中有效抑制肿瘤生长。
Absstract of: CN122624421A
本发明公开了一种超声响应性纳米药物递送系统及其制备方法与应用。本发明药物递送系统，包括具有活性氧响应的两亲性共聚物和共载于两亲性共聚物中的声敏剂与钙通道阻滞剂组成的纳米粒；纳米粒为核壳结构，两亲性共聚物由亲水段和疏水段组成，其中，疏水段形成核壳结构的内核包载声敏剂与钙通道阻滞剂，亲水段形成核壳结构的外壳。本发明制备方法，包括如下步骤：将声敏剂、钙通道阻滞剂和两亲性共聚物溶解于有机溶剂中，溶解，得到有机相；在搅拌时，将有机相滴加至水中，继续搅拌，即得。本发明纳米递送系统能规避全身性药物毒性；利用超声的时空可控性，实现两种药物的同步富集与协同作用，应用于制备治疗子宫内膜癌的药物中。
Absstract of: CN122624422A
本发明提供了一种负载甘露糖的pH/ROS双响应性功能化仿生纳米材料的制备方法及应用，该纳米材料以pH/ROS双响应材料为载体，同时负载甘露糖药物。制备所得的纳米粒，通过脂质挤出器，将功能化的巨噬细胞膜包裹在纳米粒表面以实现靶向给药。本发明提供的功能化仿生纳米颗粒在酸性和/或高活性氧微环境中可迅速释放甘露糖，进而有效促进软骨细胞细胞外基质的生成。本发明为靶向治疗软骨损伤诱导的椎间盘退变提供了一种极具前景的策略。
Nº publicación: CN122624441A 25/08/2026
Applicant:
安徽医科大学
Absstract of: CN122624441A
本发明涉及醋酸棉酚，具体涉及一种靶向递送醋酸棉酚前药化学可编程的仿生纳米颗粒及其应用；该药物递送载体具备无毒性、良好的生物相容性和制备简单的特点，此外其粒径小，靶向能力强，有利于直接靶向到肝星状细胞。此外，前药的设计使得RAET NPs 在正常生理条件下保持惰性状态，从而最大程度降低全身毒性。而在高活性氧水平的纤维化微环境中，前药选择性转化为活性形态，实现病灶部位的可控释放。
BOPI
Electronic site
